Copos Capital’s AstraZeneca AZN Stock Holding History

Copos Capital’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	$1.16M	Buy	+6,329	New	+$1.11M	0.81%	14

Other funds holding AZN

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Copos Capital's AZN Position: Q4 2025 in Review

Copos Capital opened a new position in AstraZeneca (AZN) in Q4 2025: 6,329 shares worth $1.16M. The stake represents 0.81% of the portfolio and ranks #14 among its holdings.

1,406 funds tracked by Wall St. Rank hold AZN as of Q4 2025.

Copos Capital held 6,329 shares of AstraZeneca worth $1.16M as of Q4 2025.
AstraZeneca was a new Copos Capital position in Q4 2025.
AstraZeneca made up 0.81% of Copos Capital's portfolio in Q4 2025, its #14 holding.
1,406 funds tracked by Wall St. Rank held AstraZeneca as of Q4 2025.

Based on Copos Capital's 13F filing for Q4 2025, filed 23 Feb 2026.